Switch to:
Also traded in: Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.02
UHS's Cash-to-Debt is ranked lower than
94% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 0.25 vs. UHS: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
UHS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.02 Max: 0.27
Current: 0.02
0
0.27
Equity-to-Asset 0.46
UHS's Equity-to-Asset is ranked higher than
50% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. UHS: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
UHS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.42 Max: 0.55
Current: 0.46
0.26
0.55
Debt-to-Equity 0.83
UHS's Debt-to-Equity is ranked lower than
61% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 0.62 vs. UHS: 0.83 )
Ranked among companies with meaningful Debt-to-Equity only.
UHS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23  Med: 0.71 Max: 1.98
Current: 0.83
0.23
1.98
Debt-to-EBITDA 2.41
UHS's Debt-to-EBITDA is ranked higher than
54% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 2.72 vs. UHS: 2.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
UHS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.32  Med: 2.4 Max: 5.39
Current: 2.41
1.32
5.39
Interest Coverage 10.44
UHS's Interest Coverage is ranked higher than
60% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 6.77 vs. UHS: 10.44 )
Ranked among companies with meaningful Interest Coverage only.
UHS' s Interest Coverage Range Over the Past 10 Years
Min: 5.19  Med: 9.13 Max: 48.57
Current: 10.44
5.19
48.57
Piotroski F-Score: 7
Altman Z-Score: 2.54
Beneish M-Score: -2.53
WACC vs ROIC
6.17%
9.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 12.26
UHS's Operating Margin % is ranked higher than
67% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 6.68 vs. UHS: 12.26 )
Ranked among companies with meaningful Operating Margin % only.
UHS' s Operating Margin % Range Over the Past 10 Years
Min: 7.91  Med: 13.04 Max: 13.93
Current: 12.26
7.91
13.93
Net Margin % 6.90
UHS's Net Margin % is ranked higher than
66% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. UHS: 6.90 )
Ranked among companies with meaningful Net Margin % only.
UHS' s Net Margin % Range Over the Past 10 Years
Min: 3.64  Med: 6.13 Max: 7.53
Current: 6.9
3.64
7.53
ROE % 15.14
UHS's ROE % is ranked higher than
74% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 8.45 vs. UHS: 15.14 )
Ranked among companies with meaningful ROE % only.
UHS' s ROE % Range Over the Past 10 Years
Min: 11.67  Med: 15.9 Max: 18.6
Current: 15.14
11.67
18.6
ROA % 6.85
UHS's ROA % is ranked higher than
72% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.54 vs. UHS: 6.85 )
Ranked among companies with meaningful ROA % only.
UHS' s ROA % Range Over the Past 10 Years
Min: 4.01  Med: 5.89 Max: 7.32
Current: 6.85
4.01
7.32
ROC (Joel Greenblatt) % 26.08
UHS's ROC (Joel Greenblatt) % is ranked higher than
64% of the 272 Companies
in the Global Medical Care industry.

( Industry Median: 15.26 vs. UHS: 26.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UHS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.97  Med: 23.03 Max: 28.88
Current: 26.08
15.97
28.88
3-Year Revenue Growth Rate 10.20
UHS's 3-Year Revenue Growth Rate is ranked higher than
63% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. UHS: 10.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UHS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.2  Med: 10.4 Max: 19.4
Current: 10.2
-4.2
19.4
3-Year EBITDA Growth Rate 11.40
UHS's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 6.90 vs. UHS: 11.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UHS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.3  Med: 13.8 Max: 26.7
Current: 11.4
-3.3
26.7
3-Year EPS without NRI Growth Rate 11.60
UHS's 3-Year EPS without NRI Growth Rate is ranked higher than
58% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. UHS: 11.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UHS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 20.5 Max: 73.8
Current: 11.6
-11.3
73.8
GuruFocus has detected 2 Warning Signs with Universal Health Services Inc UHS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UHS's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

UHS Guru Trades in Q1 2017

Steven Cohen 108,830 sh (New)
Andreas Halvorsen 1,728,658 sh (+392.93%)
Jana Partners 2,449,017 sh (+19.35%)
Ron Baron 156,224 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Private Capital 107,870 sh (-1.16%)
Larry Robbins 1,714,464 sh (-2.75%)
Vanguard Health Care Fund 4,289,109 sh (-5.26%)
Lee Ainslie 4,952,724 sh (-19.22%)
Robert Olstein 41,000 sh (-28.07%)
Paul Tudor Jones 7,674 sh (-38.08%)
» More
Q2 2017

UHS Guru Trades in Q2 2017

Jim Simons 517,200 sh (New)
David Dreman 153 sh (New)
Steven Cohen 180,400 sh (+65.76%)
Paul Tudor Jones 10,825 sh (+41.06%)
Larry Robbins 1,973,545 sh (+15.11%)
Lee Ainslie 5,426,487 sh (+9.57%)
Robert Olstein 44,000 sh (+7.32%)
Andreas Halvorsen 1,742,195 sh (+0.78%)
Private Capital 107,620 sh (-0.23%)
Vanguard Health Care Fund 4,225,410 sh (-1.49%)
Ron Baron 150,734 sh (-3.51%)
Jana Partners 1,360,628 sh (-44.44%)
» More
Q3 2017

UHS Guru Trades in Q3 2017

George Soros 65,100 sh (New)
Joel Greenblatt 78,782 sh (New)
Jana Partners 1,891,986 sh (+39.05%)
Robert Olstein 56,000 sh (+27.27%)
Steven Cohen 216,100 sh (+19.79%)
Larry Robbins 2,299,484 sh (+16.52%)
Private Capital 117,580 sh (+9.25%)
Lee Ainslie 5,860,821 sh (+8.00%)
Vanguard Health Care Fund 4,354,800 sh (+3.06%)
David Dreman 153 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ron Baron 112,785 sh (-25.18%)
Andreas Halvorsen 1,193,887 sh (-31.47%)
» More
Q4 2017

UHS Guru Trades in Q4 2017

Pioneer Investments 75,868 sh (New)
David Dreman 3,153 sh (+1960.78%)
George Soros 130,100 sh (+99.85%)
Larry Robbins 4,126,555 sh (+79.46%)
Steven Cohen 358,400 sh (+65.85%)
Robert Olstein 75,000 sh (+33.93%)
Private Capital 155,843 sh (+32.54%)
Joel Greenblatt 97,339 sh (+23.55%)
Vanguard Health Care Fund 4,644,600 sh (+6.65%)
Jana Partners Sold Out
Ron Baron Sold Out
Lee Ainslie 5,442,665 sh (-7.13%)
Andreas Halvorsen 673,955 sh (-43.55%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:UHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-12-31 Add 6.65%0.07%$95.77 - $115.06 $ 115.478%4,644,600
Private Capital 2017-12-31 Add 32.54%0.7%$95.77 - $115.06 $ 115.478%155,843
George Soros 2017-12-31 Add 99.85%0.2%$95.77 - $115.06 $ 115.478%130,100
Joel Greenblatt 2017-12-31 Add 23.55%0.03%$95.77 - $115.06 $ 115.478%97,339
Robert Olstein 2017-12-31 Add 33.93%0.27%$95.77 - $115.06 $ 115.478%75,000
David Dreman 2017-12-31 Add 1960.78%0.19%$95.77 - $115.06 $ 115.478%3,153
Ron Baron 2017-12-31 Sold Out 0.06%$95.77 - $115.06 $ 115.478%0
Vanguard Health Care Fund 2017-09-30 Add 3.06%0.03%$105.37 - $125 $ 115.472%4,354,800
Private Capital 2017-09-30 Add 9.25%0.17%$105.37 - $125 $ 115.472%117,580
Ron Baron 2017-09-30 Reduce -25.18%0.02%$105.37 - $125 $ 115.472%112,785
Joel Greenblatt 2017-09-30 New Buy0.13%$105.37 - $125 $ 115.472%78,782
George Soros 2017-09-30 New Buy0.22%$105.37 - $125 $ 115.472%65,100
Robert Olstein 2017-09-30 Add 27.27%0.17%$105.37 - $125 $ 115.472%56,000
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.02%$112.33 - $125.07 $ 115.47-3%4,225,410
Ron Baron 2017-06-30 Reduce -3.51%$112.33 - $125.07 $ 115.47-3%150,734
Private Capital 2017-06-30 Reduce -0.23%$112.33 - $125.07 $ 115.47-3%107,620
Robert Olstein 2017-06-30 Add 7.32%0.05%$112.33 - $125.07 $ 115.47-3%44,000
David Dreman 2017-06-30 New Buy0.01%$112.33 - $125.07 $ 115.47-3%153
Vanguard Health Care Fund 2017-03-31 Reduce -5.26%0.06%$106.71 - $126.65 $ 115.47-2%4,289,109
Private Capital 2017-03-31 Reduce -1.16%0.02%$106.71 - $126.65 $ 115.47-2%107,870
Robert Olstein 2017-03-31 Reduce -28.07%0.22%$106.71 - $126.65 $ 115.47-2%41,000
Joel Greenblatt 2017-03-31 Sold Out 0.25%$106.71 - $126.65 $ 115.47-2%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 622110    SIC: 8062
Compare:XKLS:5225, ASX:RHC, BKK:BDMS-F, LSE:NMC, NYSE:DVA, SZSE:300015, NAS:WOOF, ASX:SHL, HAM:CLS1, LSE:MDC, NYSE:EHC, NYSE:MD, NYSE:EVHC, NYSE:CHE, BKK:BH-Q, NAS:ACHC, JSE:LHC, XSGO:BANMED-SD, ASX:HSO, NYSE:AMN » details
Traded in other countries:UHS.Germany, UHID.USA,
Headquarter Location:USA
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers.

Universal Health Services owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers. Each segment contributes roughly half of the firm's overall revenue. Universal Health Services receives a significant portion of its net patient revenue from Medicare and Medicaid. The largest proportion of the firm's net patient revenue is paid by managed care organizations.

Top Ranked Articles about Universal Health Services Inc

Universal Health Services, Inc. Announces Date For 2017 Fourth Quarter And Full Year Earnings Release And Conference Call
Universal Health Services, Inc. To Present At The Leerink Partners 7th Annual Global Healthcare Conference
Lee Ainslie Ventures Into Quant Funds The former 'Tiger Cub' is heading into territory not known to the original Tiger Management group
Hedge fund founder and manager Lee Ainslie (Trades, Portfolio) has had a couple of rough years. At the same time, he has been testing quant investing strategies, a very different approach for this longtime value investor. Read more...
Universal Health Services, Inc. Announces Dividend
5 Undervalued Stocks With Growing Earnings Companies increasing their profitability
Companies growing their earnings per share are often good investments as they can return a solid profit to investors. According to the discount cash flow calculator, the following undervalued companies have grown their earnings over a five-year period. Read more...
Universal Health Services, Inc. To Present At The 36th Annual JP Morgan Healthcare Conference
Universal Health Services, Inc. Announces Dividend And Increase To Stock Repurchase Program
Universal Health Services, Inc. To Present At Two Upcoming Healthcare Conferences
Report: Developing Opportunities within Universal Health Services, Dana, Investors Real Estate, Cedar Realty, Peabody Energy, and CSRA – Future Expectations, Projections Moving into 2018
Universal Health Services, Inc. Announces Date For Third Quarter 2017 Earnings Release And Conference Call

Ratios

vs
industry
vs
history
PE Ratio 15.86
UHS's PE Ratio is ranked higher than
80% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 27.77 vs. UHS: 15.86 )
Ranked among companies with meaningful PE Ratio only.
UHS' s PE Ratio Range Over the Past 10 Years
Min: 8.1  Med: 15.36 Max: 23.97
Current: 15.86
8.1
23.97
Forward PE Ratio 13.62
UHS's Forward PE Ratio is ranked higher than
84% of the 57 Companies
in the Global Medical Care industry.

( Industry Median: 18.76 vs. UHS: 13.62 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.86
UHS's PE Ratio without NRI is ranked higher than
81% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 27.25 vs. UHS: 15.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
UHS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.26  Med: 15.72 Max: 43.19
Current: 15.86
8.26
43.19
Price-to-Owner-Earnings 17.80
UHS's Price-to-Owner-Earnings is ranked higher than
68% of the 111 Companies
in the Global Medical Care industry.

( Industry Median: 24.82 vs. UHS: 17.80 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UHS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.55  Med: 16.01 Max: 412.27
Current: 17.8
7.55
412.27
PB Ratio 2.24
UHS's PB Ratio is ranked higher than
56% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 2.52 vs. UHS: 2.24 )
Ranked among companies with meaningful PB Ratio only.
UHS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.15 Max: 3.54
Current: 2.24
1.01
3.54
PS Ratio 1.09
UHS's PS Ratio is ranked higher than
65% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. UHS: 1.09 )
Ranked among companies with meaningful PS Ratio only.
UHS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.86 Max: 1.68
Current: 1.09
0.33
1.68
Price-to-Free-Cash-Flow 22.92
UHS's Price-to-Free-Cash-Flow is ranked higher than
50% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 22.88 vs. UHS: 22.92 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UHS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.57  Med: 15.81 Max: 342.44
Current: 22.92
8.57
342.44
Price-to-Operating-Cash-Flow 10.87
UHS's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 14.54 vs. UHS: 10.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UHS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.2  Med: 8.6 Max: 24.67
Current: 10.87
3.2
24.67
EV-to-EBIT 12.14
UHS's EV-to-EBIT is ranked higher than
85% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 21.25 vs. UHS: 12.14 )
Ranked among companies with meaningful EV-to-EBIT only.
UHS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 11.8 Max: 26
Current: 12.14
6.2
26
EV-to-EBITDA 8.95
UHS's EV-to-EBITDA is ranked higher than
84% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 14.53 vs. UHS: 8.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
UHS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 8.6 Max: 12.2
Current: 8.95
4.3
12.2
EV-to-Revenue 1.46
UHS's EV-to-Revenue is ranked higher than
66% of the 271 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. UHS: 1.46 )
Ranked among companies with meaningful EV-to-Revenue only.
UHS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.4 Max: 2
Current: 1.46
0.5
2
PEG Ratio 1.96
UHS's PEG Ratio is ranked higher than
68% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 3.02 vs. UHS: 1.96 )
Ranked among companies with meaningful PEG Ratio only.
UHS' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.13 Max: 18
Current: 1.96
0.35
18
Shiller PE Ratio 23.80
UHS's Shiller PE Ratio is ranked higher than
72% of the 61 Companies
in the Global Medical Care industry.

( Industry Median: 30.03 vs. UHS: 23.80 )
Ranked among companies with meaningful Shiller PE Ratio only.
UHS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 22.26 Max: 40.68
Current: 23.8
10.2
40.68
Current Ratio 1.26
UHS's Current Ratio is ranked lower than
52% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. UHS: 1.26 )
Ranked among companies with meaningful Current Ratio only.
UHS' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.41 Max: 1.98
Current: 1.26
0.95
1.98
Quick Ratio 1.16
UHS's Quick Ratio is ranked lower than
51% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.21 vs. UHS: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
UHS' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.28 Max: 1.78
Current: 1.16
0.82
1.78
Days Inventory 43.10
UHS's Days Inventory is ranked lower than
74% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.60 vs. UHS: 43.10 )
Ranked among companies with meaningful Days Inventory only.
UHS' s Days Inventory Range Over the Past 10 Years
Min: 9.58  Med: 42.75 Max: 45.46
Current: 43.1
9.58
45.46
Days Sales Outstanding 51.74
UHS's Days Sales Outstanding is ranked lower than
62% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 40.49 vs. UHS: 51.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
UHS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.28  Med: 53.19 Max: 62.41
Current: 51.74
42.28
62.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.34
UHS's Dividend Yield % is ranked lower than
95% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 1.76 vs. UHS: 0.34 )
Ranked among companies with meaningful Dividend Yield % only.
UHS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.17  Med: 0.4 Max: 0.99
Current: 0.34
0.17
0.99
Dividend Payout Ratio 0.05
UHS's Dividend Payout Ratio is ranked higher than
99% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. UHS: 0.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
UHS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.06 Max: 0.1
Current: 0.05
0.04
0.1
3-Year Dividend Growth Rate 26.00
UHS's 3-Year Dividend Growth Rate is ranked higher than
80% of the 84 Companies
in the Global Medical Care industry.

( Industry Median: 9.40 vs. UHS: 26.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
UHS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 58.7
Current: 26
0
58.7
Forward Dividend Yield % 0.34
UHS's Forward Dividend Yield % is ranked lower than
96% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 1.84 vs. UHS: 0.34 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.79
UHS's 5-Year Yield-on-Cost % is ranked lower than
85% of the 327 Companies
in the Global Medical Care industry.

( Industry Median: 2.24 vs. UHS: 0.79 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
UHS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.4  Med: 0.93 Max: 2.31
Current: 0.79
0.4
2.31
3-Year Average Share Buyback Ratio 0.60
UHS's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.30 vs. UHS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UHS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.3  Med: 1.2 Max: 3.6
Current: 0.6
-6.3
3.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.50
UHS's Price-to-Tangible-Book is ranked lower than
88% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 3.47 vs. UHS: 10.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UHS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.04 Max: 317.57
Current: 10.5
0.84
317.57
Price-to-Intrinsic-Value-Projected-FCF 0.98
UHS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. UHS: 0.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UHS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.72  Med: 1.16 Max: 33.96
Current: 0.98
0.72
33.96
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.60
UHS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
94% of the 35 Companies
in the Global Medical Care industry.

( Industry Median: 1.62 vs. UHS: 0.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
UHS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.35  Med: 0.75 Max: 2.42
Current: 0.6
0.35
2.42
Price-to-Median-PS-Value 1.27
UHS's Price-to-Median-PS-Value is ranked lower than
68% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 1.01 vs. UHS: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UHS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.87 Max: 1.91
Current: 1.27
0.11
1.91
Price-to-Peter-Lynch-Fair-Value 1.75
UHS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
62% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. UHS: 1.75 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UHS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.4 Max: 3.71
Current: 1.75
0.4
3.71
Price-to-Graham-Number 2.72
UHS's Price-to-Graham-Number is ranked lower than
58% of the 132 Companies
in the Global Medical Care industry.

( Industry Median: 2.38 vs. UHS: 2.72 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UHS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.56  Med: 1.82 Max: 12.53
Current: 2.72
0.56
12.53
Earnings Yield (Greenblatt) % 8.22
UHS's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 273 Companies
in the Global Medical Care industry.

( Industry Median: 3.86 vs. UHS: 8.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UHS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 8.5 Max: 16.1
Current: 8.22
3.8
16.1
Forward Rate of Return (Yacktman) % 14.50
UHS's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 131 Companies
in the Global Medical Care industry.

( Industry Median: 9.05 vs. UHS: 14.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UHS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.4  Med: 18.25 Max: 30.8
Current: 14.5
4.4
30.8

More Statistics

Revenue (TTM) (Mil) $10,242.76
EPS (TTM) $ 7.28
Beta0.79
Short Percentage of Float3.17%
52-Week Range $95.26 - 129.74
Shares Outstanding (Mil)94.91

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,373 10,954 11,492
EBIT (Mil $)
EBITDA (Mil $) 1,755 1,867 1,979
EPS ($) 7.35 8.60 9.71
EPS without NRI ($) 7.35 8.60 9.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.40 0.40 0.40

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}